Last updated: August 3, 2026
Allergan USA, Inc. sued Aurobindo Pharma Ltd. in the U.S. District Court for the District of Delaware after receiving notice that Aurobindo had filed an abbreviated new drug application seeking approval for a generic version of Vraylar, the brand name for cariprazine hydrochloride. The case was an Abbreviated New Drug Application patent dispute under the Hatch-Waxman Act. The asserted patent estate principally concerned cariprazine and its pharmaceutical use.
The action did not produce a reported trial judgment establishing invalidity or infringement. The docket reflects resolution without a publicly reported merits decision. The litigation therefore operated primarily as a mechanism to establish the timing and conditions for any future generic entry.
What drug and patents were involved in Allergan v. Aurobindo?
The product at issue was Vraylar, containing cariprazine hydrochloride. Allergan marketed Vraylar for schizophrenia and bipolar disorder. The product was initially developed through the Forest Laboratories and Gedeon Richter relationship and became part of Allergan’s central central-nervous-system portfolio after Allergan acquired Forest Laboratories.
| Item |
Detail |
| Brand |
Vraylar |
| Active ingredient |
Cariprazine hydrochloride |
| Dosage form |
Oral capsules |
| NDA holder at the time |
Forest Laboratories, LLC / Allergan-related entities |
| Generic applicant |
Aurobindo Pharma Ltd. |
| Court |
U.S. District Court for the District of Delaware |
| Case number |
1:19-cv-01674 |
| Judge |
Richard G. Andrews |
| Filing period |
2019 |
| Legal basis |
Hatch-Waxman patent litigation following an ANDA Paragraph IV notice |
The principal Orange Book patent associated with the early Vraylar litigation was U.S. Patent No. 8,962,613. The patent covered cariprazine-related subject matter and was listed against Vraylar. Its expiration date was in 2029, subject to any applicable pediatric extension and other statutory adjustments reported in the Orange Book.
What patents protect Vraylar and cariprazine?
Vraylar’s protection has involved more than one patent category. The estate includes composition-related protection, solid-state or chemical-form protection, and later method-of-use and formulation claims.
Core patent categories
| Patent category |
Commercial purpose |
Generic risk |
| Cariprazine compound or salt claims |
Protect the active pharmaceutical ingredient or a defined chemical form |
High if the generic must use the claimed form |
| Polymorph and solid-state claims |
Protect crystalline or physically defined forms of cariprazine |
Depends on whether the ANDA product uses the claimed form |
| Pharmaceutical composition claims |
Protect the active ingredient in an oral dosage form |
Can create direct infringement exposure |
| Method-of-use claims |
Protect treatment of schizophrenia or bipolar disorder |
Often subject to skinny-label or labeling defenses |
| Formulation claims |
Protect capsule composition, release profile, or dosage characteristics |
Relevant if the generic duplicates the commercial formulation |
The significance of U.S. Patent No. 8,962,613 was its position as an early, long-dated patent protecting Vraylar-related subject matter. Later-issued patents may extend the listed estate, but later patents do not necessarily prevent an ANDA applicant from pursuing a launch after the earliest blocking patent expires or is removed.
Patent expiration must be evaluated patent by patent. The expiration date of a listed patent is not automatically the same as the end of all Vraylar exclusivity. Patent-term adjustment, pediatric exclusivity, terminal disclaimers, claim scope, and settlement restrictions can change the practical entry date.
What was Aurobindo’s Paragraph IV challenge?
Aurobindo’s ANDA notice apparently asserted that the relevant Vraylar patent claims were invalid, unenforceable, or would not be infringed by the proposed generic product. That type of certification is a Paragraph IV certification under the Hatch-Waxman Act.
Allergan’s filing triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the case was resolved earlier or the stay was shortened or terminated by court order. The stay prevents FDA approval during the statutory period while the patent dispute is pending.
A Paragraph IV notice does not establish that a generic will launch. It creates a litigation path. The applicant may continue defending the patent case, settle, await patent expiration, or pursue a commercial launch after the statutory and contractual restrictions lapse.
What was the litigation timeline in Allergan USA v. Aurobindo?
| Date or period |
Event |
| 2019 |
Aurobindo submitted an ANDA for generic cariprazine capsules and served a Paragraph IV notice |
| 2019 |
Allergan filed Civil Action No. 1:19-cv-01674 in Delaware |
| 2019-2020 |
The parties litigated claim construction, infringement, validity, and discovery issues |
| 2020 onward |
The case was resolved without a reported merits trial decision |
| Post-resolution |
The public record did not produce a reported Federal Circuit merits opinion establishing invalidity of the principal Vraylar patent |
The precise commercial entry date established by a confidential or partially redacted settlement cannot be inferred solely from the filing of the case. Hatch-Waxman settlements often contain launch provisions, authorized-generic terms, no-challenge clauses, supply arrangements, or contingent entry dates.
Did Allergan and Aurobindo reach a settlement?
The case was resolved without a publicly reported finding that the asserted patent was invalid or not infringed. The docket outcome is therefore best characterized as a non-merits resolution rather than a patent win for Aurobindo.
A typical settlement in this setting may provide for:
- A permitted generic launch date before patent expiration;
- An authorized-generic arrangement;
- Aurobindo’s agreement not to market before a defined date;
- Restrictions on future patent challenges;
- A license under the asserted patent;
- A confidential payment or supply arrangement.
The public docket does not establish that Aurobindo obtained an immediate launch right. The absence of a merits judgment also means that the case did not create binding precedent concerning the validity or enforceability of Vraylar’s patent estate.
What was the FDA and Orange Book status of Vraylar?
Vraylar received FDA approval as an oral cariprazine product. Its approved indications included:
- Schizophrenia in adults;
- Manic or mixed episodes associated with bipolar I disorder;
- Depressive episodes associated with bipolar I disorder.
The Orange Book listed patents associated with Vraylar, including U.S. Patent No. 8,962,613. FDA approval of an ANDA is separate from patent clearance. FDA may approve a generic after the relevant patent stay, but a generic applicant remains exposed to patent infringement claims if it launches before the patent rights are exhausted or licensed.
The Orange Book does not resolve claim construction, patent validity, settlement interpretation, or whether a proposed product infringes. Those issues remain matters for the patent litigation and any negotiated license.
When does Vraylar lose exclusivity?
Vraylar’s practical loss of exclusivity depends on three dates:
- FDA regulatory exclusivity;
- The expiration of listed patents;
- Any earlier generic launch permitted by settlement or license.
The principal early patent barrier was expected to run into 2029, subject to statutory adjustments. Regulatory exclusivity generally expires earlier than the principal patent protection. As a result, generic competition has been driven primarily by patent litigation and settlement timing rather than by FDA exclusivity alone.
A generic could obtain FDA approval before the end of the patent term but remain unable to launch commercially. Conversely, a settlement can permit entry before the nominal patent expiration date.
How strong was Allergan’s Vraylar patent estate?
The estate had meaningful commercial strength because the principal patent had a long remaining term when the case was filed and concerned the active ingredient or a closely related cariprazine product. That gave Allergan substantial leverage against an ANDA applicant.
The estate’s strength was subject to several limitations:
- The generic applicant could challenge claim validity under Sections 101, 102, 103, and 112;
- Aurobindo could argue non-infringement based on its proposed formulation or chemical form;
- Method-of-use claims could face a skinny-label strategy;
- Later patents could be narrower and easier to design around;
- A successful Paragraph IV challenge could accelerate competition materially.
The litigation record did not establish a judicial finding confirming the validity of the asserted patent. The commercial value of the estate therefore depended on settlement terms, the product’s dependence on the claimed cariprazine form, and the likelihood that Aurobindo would launch at risk.
What generic entry risks did Aurobindo create?
Aurobindo presented the standard ANDA litigation risks associated with a high-value branded CNS product:
- Earlier-than-expected generic entry;
- Price erosion after the first generic launch;
- Loss of capsule market share;
- Additional ANDA filings by other manufacturers;
- At-risk launch exposure if the patent case ended without an injunction;
- Reduced negotiating leverage in later settlements.
The first generic entrant generally has greater pricing power than later entrants. An authorized generic agreement can also reduce the commercial impact of the first independent generic by introducing a competing product at or near launch.
For Allergan, the principal exposure was not limited to Aurobindo’s volume. A successful Aurobindo challenge could have weakened the Vraylar estate for other ANDA applicants and accelerated industry-wide entry.
Which companies were likely to challenge Vraylar?
Vraylar’s commercial value and long patent runway made it a target for ANDA applicants. Aurobindo was one of the manufacturers to litigate against Allergan. Other generic companies may have filed separate ANDAs or entered related litigation, but each case must be analyzed independently because settlements, claim sets, and launch dates may differ.
A settlement with one applicant does not automatically authorize all other applicants to launch. Generic competition depends on each applicant’s ANDA status, Paragraph IV certification, litigation outcome, license terms, and regulatory approval.
What litigation affects Vraylar’s commercial outlook?
The Aurobindo case did not invalidate the Vraylar patent estate. It also did not create a reported appellate ruling narrowing or expanding Allergan’s claims. The immediate commercial effect was therefore controlled by the settlement or dismissal terms rather than by a judicial merits decision.
The principal future risks are:
- Additional Paragraph IV litigation;
- Challenges to later-issued Orange Book patents;
- A license or settlement permitting entry before 2029;
- FDA approval of multiple ANDAs after the statutory stay;
- Formulation or solid-state patents that delay or complicate launch;
- Authorized-generic competition.
Key Takeaways
- Allergan sued Aurobindo in Delaware in 2019 over an ANDA for generic Vraylar, or cariprazine hydrochloride.
- The case was a Hatch-Waxman Paragraph IV dispute.
- U.S. Patent No. 8,962,613 was a principal early Vraylar patent associated with the litigation.
- The principal patent barrier extended into 2029, subject to statutory adjustments.
- The case ended without a reported trial judgment or appellate merits ruling.
- The public docket does not establish an immediate Aurobindo launch right.
- Vraylar’s generic-entry risk depends on the settlement, later Orange Book patents, other ANDA challengers, and FDA approval timing.
- Allergan retained significant leverage because the litigation was filed while a long-dated patent remained in force.
FAQs About Allergan USA v. Aurobindo Pharma
Was Allergan v. Aurobindo a Paragraph IV case?
Yes. The action followed Aurobindo’s Paragraph IV certification challenging patent protection associated with generic cariprazine capsules.
Did Aurobindo win the Vraylar patent case?
No reported merits judgment awarded Aurobindo a finding that the asserted patent was invalid or not infringed. The case was resolved without a reported trial decision.
Can Aurobindo sell generic Vraylar immediately?
The public case outcome does not establish an immediate commercial launch right. Aurobindo’s ability to launch depends on the settlement terms, FDA approval, patent status, and any applicable license restrictions.
Does Vraylar have formulation patents?
Yes. Vraylar protection has included more than the core active-ingredient patent, with later protection potentially covering pharmaceutical compositions, solid-state forms, formulations, and methods of treatment.
What is the main investment risk from generic Vraylar?
The main risk is an earlier-than-expected generic launch that causes rapid price and volume erosion. The risk increases if another ANDA applicant invalidates a key patent or obtains a license that permits entry before the expected patent-expiration date.
References
- Allergan USA, Inc. v. Aurobindo Pharma Ltd., No. 1:19-cv-01674, U.S. District Court for the District of Delaware, docket records (2019-2020).
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). FDA.
- U.S. Food and Drug Administration. (2019). Vraylar (cariprazine hydrochloride) prescribing information. FDA.
- U.S. Patent and Trademark Office. (2015). U.S. Patent No. 8,962,613: Cariprazine hydrochloride and pharmaceutical compositions. USPTO.
- Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
